Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.

[1]  Xiaojuan Gong,et al.  Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. , 2020, ChemPlusChem.

[2]  B. Kristensen,et al.  Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. , 2020, Histology and histopathology.

[3]  A. Sood,et al.  Identifying and targeting angiogenesis-related microRNAs in ovarian cancer , 2019, Oncogene.

[4]  S. Truant,et al.  Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype , 2019 .

[5]  Karin Kornmueller,et al.  Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research , 2019, Molecules.

[6]  Yoshitaka J. Sei,et al.  Detecting the functional complexities between high-density lipoprotein mimetics. , 2018, Biomaterials.

[7]  Minghui Wang,et al.  High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma , 2018, Medicine.

[8]  Song-Cheol Kim,et al.  Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen , 2017, Oncotarget.

[9]  M. Saif,et al.  Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer , 2017, Therapeutic advances in gastroenterology.

[10]  Bhavani Nagarajan,et al.  Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging , 2016, Front. Pharmacol..

[11]  T. Zimmers,et al.  Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs , 2016, Oncotarget.

[12]  A. Gill,et al.  Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo , 2016, PloS one.

[13]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[14]  J. Knisely,et al.  Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. , 2015, Anticancer research.

[15]  Bhavani Nagarajan,et al.  HDL as a drug and nucleic acid delivery vehicle , 2015, Front. Pharmacol..

[16]  J. Samra,et al.  A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[17]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. , 2015, Journal of the National Cancer Institute.

[18]  N. Pavlakis,et al.  Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma , 2014, Clinical Cancer Research.

[19]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[20]  D. Tuveson,et al.  Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo , 2014, British Journal of Cancer.

[21]  Lawrence X. Yu,et al.  Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose. , 2014, International journal of pharmaceutics.

[22]  N. Sata,et al.  Altered Plasma Apolipoprotein Modifications in Patients with Pancreatic Cancer: Protein Characterization and Multi-Institutional Validation , 2012, PloS one.

[23]  Shobini Jayaraman,et al.  Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL. , 2012, Biochemistry.

[24]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[25]  L. Ellis,et al.  Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. , 2011, Neoplasia.

[26]  Susan R. Wilson,et al.  Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis , 2010, British Journal of Cancer.

[27]  G. Feldmann,et al.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development , 2009, Molecular Cancer Therapeutics.

[28]  T. V. van Berkel,et al.  Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. , 2001, Advanced drug delivery reviews.

[29]  Y. Shibamoto,et al.  In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. , 2001, International journal of radiation oncology, biology, physics.

[30]  J. Nolta,et al.  Immunodeficient mice as models of human hematopoietic stem cell engraftment. , 1999, Current opinion in immunology.

[31]  A. Rigotti,et al.  Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. , 1997, Journal of lipid research.

[32]  H. Greten,et al.  Biotinyl-high-density lipoproteins as a probe for the determination of high-density lipoprotein turnover in humans. , 1990, Biochimica et biophysica acta.